Do you lose muscle on Wegovy, and does it matter?

What STEP-trial data tell us about lean mass during weight loss

The STEP 1 trial (published in the New England Journal of Medicine) randomised 1,961 adults with obesity or overweight plus a weight-related condition to semaglutide 2.4mg or placebo over 68 weeks. Participants lost an average of around 15% of body weight on the active treatment. Body composition analyses from the STEP programme show that roughly 75–80% of that weight came from fat mass, with the remaining 20–25% accounted for by lean tissue. That split is not unique to semaglutide: it tracks closely with what is observed during any sustained calorie deficit. The medicine does not appear to selectively break down muscle, it reduces appetite, which reduces intake, which produces a deficit, which leads to the usual pattern of mostly-fat loss with some lean-mass reduction alongside it. Absolute muscle lost is therefore smaller the more total weight loss is driven by fat. People who lose 15kg on Wegovy lose less lean tissue in absolute terms than the percentage alone suggests, because fat is a greater share of what goes. The clinical question is not whether any lean mass is lost (it almost certainly is) but whether that loss is disproportionate, and the evidence says it is not.

Why resistance training and protein change the equation on Wegovy

The strongest lever for preserving muscle during weight loss on semaglutide is exercise, specifically resistance work. This is not new science applied to a new drug, it is the same principle that governs every supervised weight-management programme. Muscle requires a mechanical stimulus to be retained; without it, a calorie deficit will pull from lean stores more readily. The NHS England guidance on weight-management injections explicitly mentions the importance of lifestyle support (diet and physical activity) alongside these medicines, not as an afterthought but as a clinical condition of effective use. Protein is the other variable. Because Wegovy suppresses appetite considerably, some people find they eat far fewer calories than intended and, in doing so, slip below the protein amounts needed to support lean tissue. A rough working target of around 1.2–1.6g of protein per kilogram of body weight is commonly cited in sports-nutrition literature for people in a deficit, though your prescriber or a registered dietitian can give a figure suited to your situation. You can read more about practical strategies for protecting muscle on Wegovy, the short version is: lift, eat enough protein, and don't treat appetite suppression as licence to eat as little as possible.

Does losing some lean mass on semaglutide matter clinically?

For most adults, the modest lean-mass reduction seen in the STEP trials does not offset the substantial cardiovascular, metabolic and joint-load benefits of significant fat loss. Clinicians generally frame this as a favourable trade. Where it becomes more clinically relevant is in older adults, who have lower baseline muscle mass and are more vulnerable to sarcopenia, and in anyone already at the lower end of lean mass for their height. This is one reason the prescriber review matters before and during treatment, it is not just a BMI check. If muscle loss on Wegovy is a concern for you specifically, that conversation belongs in your consultation. It is also worth noting that gaining muscle while on Wegovy is possible for people who train consistently, though the calorie deficit makes net gains slower than in a surplus. The medicine's job is to reduce body weight; what you do alongside it shapes how the body composition picture looks at the end. Questions about whether semaglutide causes muscle loss in a direct pharmacological sense (rather than as a consequence of eating less) are still being investigated, but current evidence points to energy deficit as the primary driver, not any direct myotoxic effect of the drug. You can explore the full Wegovy treatment overview for context on how the medicine works more broadly.

Getting started: the clinical route through a GPhC-registered pharmacy

Wegovy is a prescription-only medicine. The legal and safe route in the UK is a prescription following a clinical assessment, no assessment, no prescription. If you are considering where to access Wegovy in the UK, it is worth verifying that any pharmacy you use is registered on the GPhC register (nume's registration number is 9012878, verifiable there directly). At nume, a GPhC-registered Independent Prescriber (a real clinician, not automated decision-making) reviews every consultation. Your pen is dispatched the same day if approved and arrives the next working day with DPD tracking, in a plain unbranded box. If muscle preservation is something you want to discuss before starting or continuing treatment, that is exactly the kind of question our prescribers address. Start your free consultation and get a clinical view on whether Wegovy is appropriate for you.